Healthcare / Medical DevicesTokyo
$711.00
-17.00 (-2.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-478.0M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$38.8B
P/E
26.3x
↑EV/EBITDA
6.1x
↓ROE
1.7%
↑Gross Margin
48.6%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.2%
FCF CAGR
—
FCF margin
-0.5%
FCF / Net income
-0.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $39.37B · net income $1.21B · FCF $-179.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $39.37B | $39.37B | $36.21B | $33.46B | $34.85B |
| Net Income | $1.21B | $1.21B | $2.19B | $2.24B | $3.73B |
| EBITDA | $3.93B | $3.93B | $3.36B | $4.40B | $6.46B |
| EPS | 22.25 | 22.25 | 40.08 | 40.49 | — |
| Gross Margin | 48.6% | 48.6% | 46.6% | 53.9% | 58.9% |
| Operating Margin | 3.4% | 3.4% | 1.2% | 6.3% | 12.9% |
| Net Margin | 3.1% | 3.1% | 6.0% | 6.7% | 10.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 5.34 | 5.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-179.0M | $-179.0M | $-4.05B | $-478.0M | $6.14B |
| Returns | |||||
| ROE | 1.7% | 1.7% | 3.0% | 3.3% | 5.6% |
| Valuation | |||||
| P/E | 26.32 | 26.32 | 18.81 | 19.83 | — |
| EV/EBITDA | 6.12 | 6.12 | 7.77 | 4.84 | 4.31 |
| P/B | 0.53 | 0.53 | 0.57 | 0.66 | 0.74 |
| Growth & Yield | |||||
| Revenue Growth | 8.7% | 8.7% | 8.2% | -4.0% | — |
| EPS Growth | -44.5% | -44.5% | -1.0% | — | — |
| Dividend Yield | 4.1% | 4.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
41.5%
EPS terminal req.
$63.09
Spread vs growth
-86.0%
5Y implied EPS CAGR
28.0%
EPS terminal req.
$76.34
Spread vs growth
-72.4%
10Y implied EPS CAGR
18.6%
EPS terminal req.
$122.94
Spread vs growth
-63.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+12.5%
Start / end P/E
16.4x → 32.0x
EPS bridge
40.08 → 22.25
Residual
-42.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.